Top-News
  • Depot
  • Watchlist
  • Glocke
  • Handeln

    • BioVaxys Technology News

    0,0577 $ -7,71% -0,0048 $
    In : 0,0539 € | 25.04.24 19:44:41 Nasdaq OTC Other aktualisieren | Orderbuch | Mehr Kurse »
    WKN: A2QE16
    ISIN: CA09076M1014
    US-Symbol: BVAXF
    Typ: Aktie

    BioVaxys Technology News

    18.04.24 - PR Newswire
    BioVaxys Technology Corp. Provides Bi-Weekly MCTO Status Update
    BioVaxys Technology Corp. Provides Bi-Weekly MCTO Status Update PR Newswire
    10.04.24 - PR Newswire
    BIOVAXYS UND SPAYVAC-FOR-WILDLIFE, INC. KÜNDIGEN DEN START EINES FELDVERSUCHS ZUR GROSS ANGELEGTEN IMMUNOKONTRAZEPTION IN DER KOMMERZIELLEN AQUAKULTURINDUSTRIE AN
    BIOVAXYS UND SPAYVAC-​FOR-WILDLIFE, INC. KÜNDIGEN DEN START EINES FELDVERSUCHS ZUR GROSS ANGELEGTEN IMMUNOKONTRAZEPTION IN DER ...
    10.04.24 - PR Newswire
    BIOVAXYS AND SPAYVAC-FOR-WILDLIFE, INC. ANNOUNCE LAUNCH OF FIELD TRIAL FOR LARGE-SCALE IMMUNOCONTRACEPTION IN THE COMMERCIAL AQUATIC FARMING INDUSTRY
    BIOVAXYS AND SPAYVAC-​FOR-WILDLIFE, INC. ANNOUNCE LAUNCH OF FIELD TRIAL FOR LARGE-​SCALE IMMUNOCONTRACEPTION IN THE COMMERCIAL AQUATIC FARMING ...
    10.04.24 - PR Newswire
    BIOVAXYS AND SPAYVAC-FOR-WILDLIFE, INC. ANNOUNCE LAUNCH OF FIELD TRIAL FOR LARGE-SCALE IMMUNOCONTRACEPTION IN THE COMMERCIAL AQUATIC FARMING INDUSTRY
    BIOVAXYS AND SPAYVAC-​FOR-WILDLIFE, INC. ANNOUNCE LAUNCH OF FIELD TRIAL FOR LARGE-​SCALE IMMUNOCONTRACEPTION IN THE COMMERCIAL AQUATIC FARMING ...
    04.04.24 - PR Newswire
    BioVaxys Technology Corp. Provides Bi-Weekly MCTO Status Update
    BioVaxys Technology Corp. Provides Bi-Weekly MCTO Status Update PR Newswire
    03.04.24 - PR Newswire
    BioVaxys Announces Allowance of DPX Formulation Patent for the United States and Filing of Additional International Patent Applications for Phase 1 DPX SurMAGE
    BioVaxys Announces Allowance of DPX Formulation Patent for the United States and Filing of Additional International Patent Applications for Phase 1 DPX SurMAGE PR Newswire
    22.03.24 - PR Newswire
    BIOVAXYS ANNOUNCES PLANNED PRIVATE PLACEMENT
    BIOVAXYS ANNOUNCES PLANNED PRIVATE PLACEMENT PR Newswire
    21.03.24 - PR Newswire
    BioVaxys Technology Corp. Provides Bi-Weekly MCTO Status Update
    BioVaxys Technology Corp. Provides Bi-Weekly MCTO Status Update PR Newswire
    08.03.24 - PR Newswire
    BioVaxys Technology Corp. Granted Voluntary Management Cease Trade Order
    BioVaxys Technology Corp. Granted Voluntary Management Cease Trade Order PR Newswire
    08.03.24 - PR Newswire
    BioVaxys Technology Corp. Granted Voluntary Management Cease Trade Order
    BioVaxys Technology Corp. Granted Voluntary Management Cease Trade Order PR Newswire
    07.03.24 - PR Newswire
    BioVaxys Technology Corp. Provides Bi-Weekly MCTO Status Update
    BioVaxys Technology Corp. Provides Bi-Weekly MCTO Status Update PR Newswire
    05.03.24 - PR Newswire
    BioVaxys Announces Allowance of DPX-Related Patent for Japan and Filing of Additional International Patent Applications
    BioVaxys Announces Allowance of DPX-​Related Patent for Japan and Filing of Additional International Patent Applications PR Newswire
    21.02.24 - PR Newswire
    Annual Financial Statements Update for the Year Ended October 31, 2023
    Annual Financial Statements Update for the Year Ended October 31, 2023 PR Newswire
    21.02.24 - PR Newswire
    BIOVAXYS COMPLETES THE ACQUISITION OF ALL INTELLECTUAL PROPERTY, IMMUNOTHERAPEUTICS PLATFORM TECHNOLOGY, AND CLINICAL STAGE ASSETS OF THE FORMER IMV INC.
    BIOVAXYS COMPLETES THE ACQUISITION OF ALL INTELLECTUAL PROPERTY, IMMUNOTHERAPEUTICS PLATFORM TECHNOLOGY, AND CLINICAL STAGE ASSETS OF THE ...
    21.02.24 - PR Newswire
    BIOVAXYS COMPLETES THE ACQUISITION OF ALL INTELLECTUAL PROPERTY, IMMUNOTHERAPEUTICS PLATFORM TECHNOLOGY, AND CLINICAL STAGE ASSETS OF THE FORMER IMV INC.
    BIOVAXYS COMPLETES THE ACQUISITION OF ALL INTELLECTUAL PROPERTY, IMMUNOTHERAPEUTICS PLATFORM TECHNOLOGY, AND CLINICAL STAGE ASSETS OF THE ...
    13.02.24 - PR Newswire
    BioVaxys erwirbt das gesamte geistige Eigentum, die Immuntherapeutika-Plattformtechnologie und die Vermögenswerte im klinischen Stadium der ehemaligen IMV Inc.
    BioVaxys erwirbt das gesamte geistige Eigentum, die Immuntherapeutika-​Plattformtechnologie und die Vermögenswerte im klinischen Stadium der ehemaligen IMV Inc. PR Newswire
    12.02.24 - PR Newswire
    BioVaxys Acquires All Intellectual Property, Immunotherapeutics Platform Technology, and Clinical Stage Assets of the Former IMV Inc.
    BioVaxys Acquires All Intellectual Property, Immunotherapeutics Platform Technology, and Clinical Stage Assets of the Former IMV Inc. PR Newswire
    12.02.24 - PR Newswire
    BioVaxys Acquires All Intellectual Property, Immunotherapeutics Platform Technology, and Clinical Stage Assets of the Former IMV Inc.
    BioVaxys Acquires All Intellectual Property, Immunotherapeutics Platform Technology, and Clinical Stage Assets of the Former IMV Inc. PR Newswire
    11.02.24 - PR Newswire
    BIOVAXYS GIBT ABSCHLUSS DER ERSTEN TRANCHE DER PRIVATPLATZIERUNG BEKANNT
    BIOVAXYS GIBT ABSCHLUSS DER ERSTEN TRANCHE DER PRIVATPLATZIERUNG BEKANNT PR Newswire
    11.02.24 - PR Newswire
    BIOVAXYS GIBT ABSCHLUSS DER LETZTEN TRANCHE DER PRIVATPLATZIERUNG BEKANNT
    BIOVAXYS GIBT ABSCHLUSS DER LETZTEN TRANCHE DER PRIVATPLATZIERUNG BEKANNT PR Newswire

    Newssuche

    Videos

    newspaper
    26.04.24 +6,31%
    Technical Trading: Gold Long freitags
    Gold Long Typ: Turbo Open End WKN: NG8DB8 Hebel: 27 Laufzeit: OpenEnd Einstieg: Market ... Mehr »